In vitro contracture test and gene typing in diagnosing malignant hyperthermia;In-vitro-kontrakturtest und gentypisierung in der maligne hyperthermie- diagnostik: Ein beispiel fur die sinnvolle erganzung beider methoden

Anaesthesist

Volumn 49, Issue 2, 2000, Pages 113-120

  Ruffert H ^a   Olthoff, D ^a   Deutrich, C ^a   Thamm, B ^a   Froster, U ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Genotyping; In vitro contracture test; Malignant Hyperthermia; MH diagnosis

Indexed keywords

ARTICLE; CLINICAL ARTICLE; GENE AMPLIFICATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MALIGNANT HYPERTHERMIA; PHENOTYPE;

EID: 0034011969     PISSN: 00032417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001010050017     Document Type: Article

References (32)

1. Adeokun AM, West SP, Ellis FR, Halsall PJ, Hopkins PM, Foroughmand AM, Iles DE, Robinson RL, Stewart AD, Curran JL (1997) The G1021A substitution in the RYR1 gene does not cosegregate with malignant hyperthermia susceptibility in a British pedigree. Am J Hum Genet 60:833-841
2. Barone V, Massa O, Intravaia E, Bracco A, Di Martino A, Tegazzin V, Cozzolino S, Sorrentino V (1999) Mutation screening of RYR1 gene and identification of two novel mutations in Italian malignant hyperthermia families. J Med Genet 36:115-118
3. Deufel T, Golla A, Iles D, Meindl A, Meitinger T, Schindelhauer D, DeVries A, Pongratz D, MacLennan DH, Johnson KJ, Lehmann-Horn F (1992) Evidence for genetic heterogeneity of malignant hyperthermia susceptibility. Am J Hum Genet 50:1151-1161
4. Deufel T, Sudbrak R, Feist Y, Rübsam B, DuChesne J, Schäfer KL, Roewer N, Grimm T, Lehmann-Horn F, Hartung E, Müller CR (1995) Discordance, in a malignant hyperthermia pedigree, between in vitro contracture-test phenotypes and haplotypes for the MHS 1 region on chromosome 19q12-13.2, comprising the C1840-T transition in the RYR1 gene. Am J Hum Genet 56:1334-1342
5. The European Malignant Hyperpyrexia Group (1984) A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. Br J Anaesth 56:1267-1269
6. Fortunate G, Carsana A, Tinto N, Brancadoro V, Canfora G, Salvatore F (1999) A case of discordance between genotype and phenotype in a malignant hyperthermia family. Eur J Hum Genet 7:415-420
7. Fujii J, Otsu K, Zorzato F, de Leon S, Khanna VK, Weiler J, O'Brien PJ, MacLennan DH (1991) Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia. Science 253:448-451
8. Gillard S, Derdemezi J, Britt BA, Duff CL, Worton RG, MacLennan DH (1991) A substitution of cysteine for arginine 614 in the ryanodine receptor is potentially causative of human malignant hyperthermia. Genomics 11:751-755
9. Harrison GG (1975) Control of the malignant hxperpyrexic syndrome in the MHS swine by dantrolene sodium. Br J Anaesth 47:62-65
10. Hogan K (1997) Molecular medicine and malignant hyperthermia. Anesthesiology 86:511-513
11. Hopkins PM, Hartung E, Wappler F (1998) The European Malignant Hyperthermia Group: Multicentre evaluation of ryanodine contracture testing in malignant hyperthermia. Br J Anaesth 80:389-394
12. 2/δ-subunit of the L-type voltage-dependent calcium channel to chromosome 7q and analysis of the segregation of flanking markers in malignant hyperthermia susceptible families. Hum Mol Genet 3:969-975
13. Kalow W (1987) Inheritance of malignant hyperthermia: a review of published data. In: Britt BA (ed) Malignant hyperthermia. Martinus-Nijhoff, Amsterdam, pp 155-179
14. Keating KE, Quane KA, Manning BM, Lehane M, Härtung E, Censier K, Urwyler A, Klausnitzer M, Muller CR, Heffron JJA, McCarthy TV (1994) Detection of a novel RYR1 mutation in four malignant hyperthermia pedigrees. Hum Mol Genet 3:1855-1858
15. Larach MG, Rosenberg H, Larach DR, Broennle M (1987) Prediction of malignant hyperthermia susceptibility by clinical signs. Anesthesiology 66:547-550
16. Larach MG, Mac Lennan DH (1999) How carefully can we phenotype patients suspected of malignant hyperthermia susceptibility? Anesthesiology 90:645-684
17. Levitt RC, Olckers A, Meyers S, Levitt MK, Rosenberg H, Fletcher JE, Isaacs H, Meyers DA (1992) Evidence for the localization of a malignant hyperthermia susceptibility locus to human chromosome 17q. Genomics 14:562-566
18. 2+ release channel function and severe central core disease. Proc Natl Acad Sci USA 96:4164-4169
19. Manning BM, Quane KA, Ording H, Urwyler A, Tegazzin V, Lehane M, O'Halloran J, Hartung E, Giblin LM, Lynch PJ, Vaughan P, Censier K, Bendixen D, Comi G, Heytens L, Monsieurs K, Fagerlund T, Wolz W, Heffron JJA, Muller CR, McCarthy TV (1998) Identification of novel mutations in the ryanodine-receptor gene (RYR1) in malignant hyperthermia: genotype-phenotype correlation. Am J Hum Genet 62:599-609
20. Manning BM, Quane KA, Lynch PJ, Urwyler A, Tegazzin V, Krivosic-Horber R, Censier K, Comi G, Adnet P, Wolz W, Lunardi J, Muller CR, McCarthy TV (1998) Novel mutations at a CpG dinucleotide in the ryanodine receptor in malignant hyperthermia. Hum Mutat 11:45-50
21. McCarthy TV, Healy JMS, Heffron JJA, Lehane M, Deufel T, Lehmann-Horn F, Farrall M, Johnson K (1990) Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. Nature 343:562-564
22. McCarthy TV, O'Halloran J, The European Malignant Hyperthermia Group (1998) Genotype phenotype correlation in malignant hyperthermia susceptibility. Acta Anaesthesiol Scand [Suppl 112] 42:206-209
23. Monnier N, Procaccio V, Stieglitz P, Lunardi J (1997) Malignant-hyperthermia susceptibility is associated with a mutation of the alpha-1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. Am J Hum Genet 60:1316-1325
24. Ørding H, European Malignant Hyperthermia Group (1997) In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH-Group: Results of testing patients surviving fulminant MH and unrelated low-risk subjects. Acta Anaesthesiol Scand 41:955-966
25. Ørding H, Glahn K, Gardi T, Fagerlund T, Bendixen D (1997) 4-Chloro-m-cresol test-A possible supplementary test for diagnosis of malignant hyperthermia susceptibility. Acta Anaesthesiol Scand 41:967-972
26. Otsu K, Phillips MS, Khanna VK, de Leon S, MacLennan DH (1992) Refinement of diagnostic assays for a probable causal mutation for porcine and human malignant hyperthermia. Genomics 13:835-837
27. Phillips MS, Fujii J, Khanna VK, DeLeon S, Yokobata K, DeJong PJ, MacLennan DH (1996) The structural organization of the human skeletal muscle ryanodine receptor (RYR1) gene. Genomics 34:24-41
28. Richter M, Schleithoff L, Deufel T, Lehmann-Horn F, Herrmann-Frank A (1997) Functional characterisation of a distinct ryanodine receptor mutation in human malignant hyperthermia-susceptible muscle. J Biol Chem 272:5256-5260
29. Serfas K, Bose D, Patel L, Wrogeman K, Phillips M, MacLennan D, Greenberg C (1996) Comparison of the segregation of the RYR1 C1840 T mutation with segregation of the caffeine/halothane contracture test results for malignant hyperthermia susceptibility in a large Manibota Mennonite family. Anesthesiology 84:322-329
30. Sudbrak R, Procaccio V, Klausnitzer M, Curran JL, Monsieurs SK, Van Broeckhoven C, Ellis R, Heyetens L, Härtung FJ, Kozak-Ribbens G, Heilinger D, Weissenbach J, Lehmann-Horn F, Mueller CR, Deufel T, Stewart AD, Lunardi J (1995) Mapping of a further malignant hyperthermia susceptibility locus to chromosome 3q13.1. Am J Hum Genet 56:684-691
31. 2+ release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with hyperthermia and/or central core disease. J Biol Chem 272:26332-26339
32. Zhang Y, Chen HS, Khanna VK, De Leon S, Phillips MS, Schappert K, Britt BA, Brownell AKW, MacLennan DH (1993) A mutation in the human ryanodine receptor gene associated with central core disease. Nature Genet 5:46-50